GSA Capital Partners LLP purchased a new position in Atyr Pharma Inc. (NASDAQ:LIFE) during the second quarter, Holdings Channel reports. The firm purchased 36,498 shares of the company’s stock, valued at approximately $101,000. GSA Capital Partners LLP owned approximately 0.15% of Atyr Pharma at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Jackson Park Capital LLC purchased a new stake in shares of Atyr Pharma during the second quarter worth approximately $183,000. Emerald Acquisition Ltd. purchased a new stake in shares of Atyr Pharma during the second quarter worth approximately $206,000. State Street Corp increased its stake in shares of Atyr Pharma by 51.8% in the first quarter. State Street Corp now owns 68,285 shares of the company’s stock worth $270,000 after buying an additional 23,290 shares during the last quarter. Finally, BlackRock Fund Advisors increased its stake in shares of Atyr Pharma by 4.6% in the first quarter. BlackRock Fund Advisors now owns 464,476 shares of the company’s stock worth $1,830,000 after buying an additional 20,539 shares during the last quarter. 44.75% of the stock is currently owned by hedge funds and other institutional investors.
Atyr Pharma Inc. (NASDAQ:LIFE) traded up 3.42% during midday trading on Wednesday, hitting $3.33. 57,611 shares of the stock were exchanged. The firm’s 50-day moving average is $3.17 and its 200 day moving average is $3.31. The stock’s market cap is $78.98 million. Atyr Pharma Inc. has a 52 week low of $2.48 and a 52 week high of $13.26.
Atyr Pharma (NASDAQ:LIFE) last issued its earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.06. Equities research analysts expect that Atyr Pharma Inc. will post ($2.56) EPS for the current fiscal year.
A number of equities research analysts recently commented on LIFE shares. Zacks Investment Research upgraded shares of Atyr Pharma from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Tuesday, August 16th. Citigroup Inc. raised their price objective on shares of Atyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a research report on Tuesday, August 16th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $6.00.
Atyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Want to see what other hedge funds are holding LIFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atyr Pharma Inc. (NASDAQ:LIFE).
Receive News & Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.